SCHEMBL13627972

SCHEMBL13627972

O=C1/C(=N\O)c2cc(F)ccc2N1Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
HPGD P15428 2/20 0.57
HTT P42858 2/20 0.57
CASP1 P29466 2/20 0.50
CASP3 P42574 2/20 0.50
CASP7 P55210 2/20 0.50
CASP4 P49662 1/20 0.50
CASP9 P55211 1/20 0.50
CASP6 P55212 1/20 0.50
CASP8 Q14790 1/20 0.50
TRPA1 O75762 1/20 0.45
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
CA1 P00915 1/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627915 0.92 CASP1 (0.56) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13627938 0.88 CA12 (0.52) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13627951 0.87 ALDH1A1 (0.72) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13627946 0.86 UBE2N (0.56) ALDH1A1HPGDTRPA1CA2CA9
SCHEMBL13627911 0.86 CASP3 (0.56) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13628005 0.84 CHRM5 (0.56) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13627910 0.83 CASP1 (0.72) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13627913 0.83 CASP1 (0.56) ALDH1A1HPGDHTTCASP1CASP3
SCHEMBL13627936 0.83 TRPA1 (0.62) ALDH1A1TRPA1MAPT
SCHEMBL13627948 0.82 TRPA1 (0.48) ALDH1A1HPGDTRPA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885HPGD 1551/4885HTT 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.